Antimicrobial resistance in the Pacific Island countries and territories.

antimicrobial resistance antimicrobial stewardship antimicrobial use pacific island countries and territories surveillance

Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
04 2020
Historique:
received: 19 02 2020
revised: 26 03 2020
accepted: 27 03 2020
entrez: 1 5 2020
pubmed: 1 5 2020
medline: 25 6 2021
Statut: ppublish

Résumé

Antimicrobial resistance (AMR) is a critical global health threat with a disproportionate impact on low-income and middle-income countries (LMICs) due to their higher burden of infections, reduced laboratory surveillance infrastructure and fewer regulations governing antimicrobial use among humans or animals. While there have been increasing descriptions of AMR within many LMICs in WHO's Western Pacific and South East Asian regions, there remains a paucity of data from Pacific Island countries and territories (PICTs). The PICTs represent 22 predominantly middle-income countries and territories with a combined population of 12 million people and 20 official languages, spread over hundreds of separate islands spanning an area corresponding to more than 15% of the earth's surface. Our paper outlines the present state of the evidence regarding AMR in PICTs-discussing the present estimates of AMR and their accompanying limitations, important drivers of AMR, as well as outlining key priorities and potential solutions for tackling AMR in this region. Significant areas for action include developing National Action Plans, strengthening laboratory surveillance systems and educational activities targeted at both healthcare workers and the wider community. Ensuring adequate funding for AMR activities in PICTs is challenging given competing health and environmental priorities, in this context global or regional funding initiatives such as the Fleming Fund can play a key role.

Identifiants

pubmed: 32349993
pii: bmjgh-2020-002418
doi: 10.1136/bmjgh-2020-002418
pmc: PMC7213808
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Clin Microbiol. 2005 Sep;43(9):4826-9
pubmed: 16145150
J Prim Health Care. 2009 Mar;1(1):30-5
pubmed: 20690484
Lancet. 2016 Jan 16;387(10015):285-95
pubmed: 26603921
Int J Antimicrob Agents. 2016 Jul;48(1):27-32
pubmed: 27318624
Lancet Glob Health. 2019 Jan;7(1):e119-e131
pubmed: 30554748
J Glob Antimicrob Resist. 2019 Mar;16:81-82
pubmed: 30445212
Infect Dis Clin North Am. 2019 Mar;33(1):231-245
pubmed: 30712764
Paediatr Int Child Health. 2018 Nov;38(4):261-265
pubmed: 30079842
Pharm Pract (Granada). 2007 Jan;5(1):36-41
pubmed: 25214916
P N G Med J. 2009 Mar-Jun;52(1-2):28-34
pubmed: 21125988
Antibiotics (Basel). 2019 Mar 19;8(1):
pubmed: 30893880
PLoS Med. 2016 Nov 29;13(11):e1002184
pubmed: 27898664
Sex Transm Infect. 2013 Dec;89 Suppl 4:iv19-23
pubmed: 24243875
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Trop Anim Health Prod. 2018 Oct;50(7):1547-1558
pubmed: 29679359
Lancet Glob Health. 2017 Dec;5(12):e1186-e1187
pubmed: 29132611
Curr Diab Rep. 2015 May;15(5):29
pubmed: 25809458
BMJ. 2017 Sep 5;358:j2687
pubmed: 28874365
Am J Trop Med Hyg. 2015 Nov;93(5):1031-7
pubmed: 26283748
Lancet. 2016 Jan 9;387(10014):188-98
pubmed: 26603919
J Antimicrob Chemother. 2017 Nov 1;72(11):2963-2972
pubmed: 28961709
Int J Food Microbiol. 2012 Jun 15;157(1):102-7
pubmed: 22607809
Int J Infect Dis. 2017 Apr;57:138-143
pubmed: 28216179
J Travel Med. 2019 Dec 23;26(8):
pubmed: 31115466
Intern Med J. 2019 Apr;49(4):461-466
pubmed: 30230153
Environ Int. 2018 Jan;110:160-172
pubmed: 29107352
BMJ Glob Health. 2019 May 9;4(3):e001239
pubmed: 31179029
Lancet. 2011 Jan 15;377(9761):228-41
pubmed: 21146207
Lancet. 2016 Jan 9;387(10014):168-75
pubmed: 26603918

Auteurs

Michael Loftus (M)

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia anton.peleg@monash.edu michael.loftus@monash.edu.

Andrew Stewardson (A)

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.

Ravi Naidu (R)

Colonial War Memorial Hospital, Suva, Fiji.

Ben Coghlan (B)

Health Security Program, Burnet Institute, Melbourne, Victoria, Australia.

Adam Jenney (A)

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, Fiji.

Jonila Kepas (J)

Medical Standards Division, Government of Papua New Guinea National Department of Health, Port Moresby, National Capital District, Papua New Guinea.

Evelyn Lavu (E)

Central Public Health Laboratory, Government of Papua New Guinea National Department of Health, Port Moresby, National Capital District, Papua New Guinea.

Alex Munamua (A)

National Referral Hospital, Honiara, Solomon Islands.

Trisha Peel (T)

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.

Vinita Sahai (V)

Colonial War Memorial Hospital, Suva, Fiji.

Rosemary Tekoaua (R)

Laboratory Services, Government of the Republic of Kiribati Ministry of Health and Medical Services, Tarawa, Kiribati.

Litia Tudravu (L)

Colonial War Memorial Hospital, Suva, Fiji.

Julie Zinihite (J)

National Pharmacy Division, Solomon Islands Ministry of Health and Medical Services, Honiara, Solomon Islands.

Allen Cheng (A)

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Eric Rafai (E)

Fiji Ministry of Health and Medical Services, Suva, Fiji.

Anton Peleg (A)

Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia anton.peleg@monash.edu michael.loftus@monash.edu.
Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH